The Mumbai based Aanjaneya Lifecare Company which operates in pharma sector, is coming out with its Initial Public Offering or IPO.
In this article, we will look at the Review, Analysis and Details of the Aanjaneya Lifecare IPO.
Aanjaneya Lifecare IPO: Review Analysis & Details
Some basic details first about the Aanjaneya Lifecare IPO, which are available as of now:
Image sourced from Official website of Aanjaneya Lifecare- The size of Aanjaneya Lifecare IPO is around 1.2 billion or 120 Crore Rs. INR
- The company claims to be the largest Quinine producers in world
- The company seems to have a strong product line - Alkaloids, Anti Malarial APIs & Anti Cancer APIs from Natural Sources & Veterinary APIs. In Finished Dosages we cover important therapeutic areas such as Anti Malarial, Anti Cancer, Erectile Dysfunction, Hormone Replacement Therapy, Anti Obesity, Herbal products & Lozenges for various Therapeutic segments
What is the issue size of the Aanjaneya Lifecare IPO?
Around 120 Crore Rs is the size of the Aanjaneya Lifecare IPO.
What is the price band of Aanjaneya Lifecare IPO?
The price band for Aanjaneya Lifecare IPO is Rs. 228 to 240 Rs per share.
How many shares will be sold in the Aanjaneya Lifecare IPO?
The total no. of shares to be sold through this IPO is 50 lakh shares fresh shares.
What are the IPO dates for Aanjaneya Lifecare IPO
The IPO dates for Aanjaneya Lifecare IPO are from May 9, 2011 to May 12, 2011
How will the capital raised by Aanjaneya Lifecare IPO be used?
It is reported that the capital raised through this IPO will be used for 3 purposes:
- set up of anti-cancer API facility
- expansion of existing Research & Development facilities
- Branding of products in international markets
Other Current IPO's: Sanghvi Forgings IPO and Vaswani Industries IPO
See List of All IPO Articles here
Any ratings given to Aanjaneya Lifecare IPO?
Fitch has assigned a grade 2 to Aanjaneya Lifecare IPO
What are the analysts recommendations and business results for Aanjaneya Lifecare IPO?
Size of the IPO is compratively large as compared to the other IPO's which are currently open.
Fitch has assigned a rating of 2 to this IPO, which does not paint a very rosy picture. Pharma sector is always under the watch of the regulators and things become really tough when companies have to do business at international level as various standards, norms and regulations are to be followed as per the local country. Then comes the competition, at local as well as international level.
However, on the positive side, pharma sector and individual pharma companies, are known to spring surprises every now and then. Say, a company gets patent for a drug in USA or wins a court case against the rival to justify its medicines result in sudden rallies in the pharma stock.
Aanjaneya Lifecare is coming out to the stock market, so dont expect much of sudden rallies. One needs to keep a long term outlook for such companies, which is still not risk-free.
Anand Rathi Advisors and IDBI Capital are BRLM Book Running Lead Managers to the issue.
No comments:
Post a Comment